drug adverse effects of phosphodiesterase-5-inhibitors
Jump to navigation
Jump to search
Adverse effects
- adverse ocular effects
- blurred vision
- cataracts
- changes in color perception
- conjunctivitis
- dry eyes
- eye hemorrhage
- eye pain
- mydriasis
- small number of post-marketing reports of sudden vision loss, attributed to NAION (non arteritic ischemic optic neuropathy) Viagra, Cialis & Levitra specifically implicated.[1]
- risk for serous retinal detachment & retinal vascular occlusion[6]
- no adverse visual or retinal effects associated with daily administration of tadalafil or sildenafil for 6 months[3]
- absolute risk is low[6]
- reports of sudden hearing loss[2], generally unilateral, sometimes persistent, tinnitus may be associated
- headache[4]
- flushing[4]
- dyspepsia[4]
- rhinitis[4]
- back pain/myalgias (tadalafil, others ?)[4]
- increased risk of cutaneous melanoma[2] (RR=1.21)*
- increased risk of basal cell carcinoma (BCC)[2] (RR=1.19)*
* downregulation of PDE5 is thought to increase invasiveness of melanoma; however, risk > for stages 0 & 1 but not stages 2-4 & no dose-response effect
* no plausible mechanism for increased risk of BCC
More general terms
References
- ↑ 1.0 1.1 http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#ED
- ↑ 2.0 2.1 2.2 2.3 Prescriber's Letter 14(12): 2007 Sudden hearing loss with Viagra, Levitra, Cialis, and Revatio Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=231204&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Cordell WH et al, Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil Archives of Ophthalmology 2009;127(4):367-373 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19365010
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
- ↑ Schwenk TL Association Between Erectile Dysfunction Drugs and Malignant Melanoma NEJM Journal Watch. June 23, 2015 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Loeb S et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015 Jun 23; 313:2449 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26103029 - ↑ 6.0 6.1 6.2 Etminan M, Sodhi M, Mikelberg FS et al Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US. JAMA Ophthalmol. Published online April 7, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35389459 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2790661